BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the efficacy, safety and tolerability of a new
investigational protease inhibitor (PI) plus background antiretrovirals plus Fuzeon (90mg sc
bid) in HIV-1 infected, triple-class treatment-experienced, Fuzeon-naive adults. The new
investigational PI will be administered according to the procedures of the early access
program in which the patient is enrolled. The anticipated time on study treatment is 3-12
months, and the target sample size is approximately 120 individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborator:
Trimeris
Treatments:
Darunavir Enfuvirtide HIV Protease Inhibitors Protease Inhibitors